Xtoro topical finafloxacin regulatory update

FDA approved an NDA from Novartis’ Alcon Inc. unit for topical Xtoro finafloxacin to treat acute otitis externa (swimmer’s ear) caused by susceptible strains of Pseudomonas aeruginosa and Staphylococ...